Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Medicare's Drug Price Negotiation Program is delivering real savings for many enrollees in 2026 — but not all. A Vanderbilt study found that patients on moderately priced drugs saved 26%–42% on out-of-pocket costs, while those on the priciest drugs saw no additional benefit because they'd already hit the $2,100 annual spending cap.
Medicare's Drug Price Negotiation Program (MDPNP), launched at the start of 2026 under the Inflation Reduction Act, is delivering meaningful savings — but with a catch. A new Vanderbilt University study found that six of the nine drugs analyzed resulted in significant out-of-pocket savings for beneficiaries, while three of the highest-priced drugs offered no additional relief.
The reason? Patients on the costliest drugs — like Stelara, Imbruvica, and Enbrel — already hit the $2,100 annual out-of-pocket cap introduced in 2025, so the newly negotiated prices didn't translate into extra savings for them. Meanwhile, patients on drugs like Eliquis, Jardiance, Entresto, and Xarelto — all priced below the cap — saw direct savings automatically flow through their insurance plans, with no action required on their part.
By the Numbers:
Why it matters: The MDPNP marks a landmark shift in how the U.S. government negotiates drug prices, and this early data shows it's working — at least for patients in the middle of the cost spectrum. For the highest-need patients, the out-of-pocket cap is doing the heavy lifting, but the negotiation program itself isn't yet adding value for them.
